Table 3.
Univariate analysis for prognosis of patients with NSCLC
| Variables | Univariate
|
Multivariate*
|
||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Sex | 0.2770 | |||
| Male | 1.237 (0.843, 1.816) | |||
| Female | ||||
| Age (years) | 0.1956 | |||
| >60 | 1.268 (0.885, 1.816) | |||
| ≤ 60 | ||||
| TNM stage | 0.932 | |||
| IV | 1.016 (0.700, 1.475) | |||
| III | ||||
| Location | 0.941 | |||
| Peripheral | 0.941 (0.619, 1.430) | |||
| Central | ||||
| VEGF (pg/mL) | 0.0494 | 0.024 | ||
| >280 | 1.539 (1.001, 2.365) | 1.600 (1.063, 2.408) | ||
| ≤280 | ||||
| PLT (×109/L) | 0.4046 | |||
| >300 | 0.815 (0.503, 1.319) | |||
| ≤300 | ||||
| VEGFPLT (×10−6 pg) | 0.1288 | |||
| >0.55 | 1.326 (0.921, 1.909) | |||
| ≤ 0.55 | ||||
| ΔVEGFPLT | 0.7380 | |||
| >0.005 | 1.064 (0.738, 1.534) | |||
| ≤ 0.005 | ||||
| CR + PR (pg/mL) | 0.7390 | |||
| VEGF >280 | 1.112 (0.596, 2.074) | |||
| VEGF ≤280 | ||||
| SD + PD (pg/mL) | 0.0310 | 0.0224 | ||
| VEGF >280 | 1.935 (1.062, 3.527) | 2.087 (1.110, 3.926) | ||
| VEGF ≤280 | ||||
Note:
*
Adjusted for age and sex.
Abbreviations: ΔVEGFPLT, the minus value of VEGFPLT before the first cycle minus the value after the chemotherapy; CI, confidence interval; CR, complete response; HR, hazard ratio; NSCLC, non-small cell lung cancer; PD, progressive disease; PLT, platelets; PR, partial response; SD, stable disease; TNM, tumor node metastasis; VEGF, vascular endothelial growth factor; VEGFPLT, VEGF load per platelet.